Skip to main content

$0.155 -0.005 (-3.13%)

High

$0.17

Low

$0.16

Trades

36

Turnover

$26,369

Volume

167,225
30 June 2023 at 4:10pm
Register to track LGP and receive email alerts.

Ethics approval granted for psilocybin clinical trial

StockBot

416,823 posts

LGP released this announcement to the ASX on 15 February 2023, 9:28. The announcement is marked as price sensitive, and is 5 page(s) in length and 549.62kb in size.

You can view all announcements from LGP and see how they appear on a price chart on the announcements page.

At the date of this announcement, LGP was 0.006% short sold according to ASIC data. It was ranked the 560th most shorted stock on the ASX. It remains ranked 643rd as of the latest reported data (10 February 2025).

Other Recent Announcements from LGP
Annual Report to shareholders 30 June 2023, 9:38
Corporate Governance Statement and Appendix 4G 30 June 2023, 8:47
Preliminary Final Report 31 May 2023, 10:16
Ethics approval granted for psilocybin clinical trial 15 February 2023, 9:28
Ceasing to be a substantial holder 8 February 2023, 18:58
Psilocybin and MDMA down-scheduled 6 February 2023, 10:39
Amended Constitution 2 February 2023, 16:23
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track LGP and receive email alerts.